Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 By Investing.com

Stifel reiterated a Buy on Trevi Therapeutics with an $18 price target versus a $14.66 share price, while analyst targets range from $16 to $27. The company says it has about $334 million pro forma cash, enough to fund operations through 2030, and is moving its pivotal Haduvio IPF-CC program forward this quarter after an FDA end-of-phase-2 meeting. Trevi also plans a phase 2b renal cell carcinoma study in Q2 2026, with top-line data expected in Q4 2026.

Analysis

TRVI is shifting from a “story stock” into a duration trade: the market is now underwriting a multi-year clinical runway rather than near-term commercialization. That changes the investor base from fast-money biotech momentum to longer-horizon funds willing to pay for cash-backed optionality, but it also caps upside unless the first pivotal readouts reduce regulatory ambiguity. The key second-order effect is that a large cash cushion lowers dilution risk, which should compress the company’s financing discount versus earlier-stage peers with similar pipelines.

The main setup is not the headline indication, but the platform expansion potential. If management can convert one lung-disease pathway into a broader interstitial lung disease franchise, the implied addressable market can re-rate faster than the actual data arrives, because investors will capitalize the expansion probability long before 2027 readouts. That said, a two-trial design still leaves a binary gap: any protocol slippage, enrollment delay, or FDA pushback on endpoints would push the value reset out by 12-18 months and likely unwind part of the recent rerating.

The contrarian read is that the market may be overpaying for “cash runway as de-risking.” In biotech, long runway is helpful only if it funds value-inflecting milestones; otherwise it simply delays the next financing and keeps the catalyst stack thin. Near-term upside is probably dominated by positioning and sell-side credibility, while the real inflection is whether early tolerability or mechanistic signal in the broader ILD program emerges before the pivotal IPF readout.

Competitive dynamics matter because a successful read could force larger pulmonary and fibrosis players to reassess licensing and BD interest, especially if the asset shows utility across multiple ILD subtypes. Conversely, if the broader program disappoints, capital will likely rotate back to higher-quality biotech names with nearer data and clearer commercial paths, leaving TRVI as a long-dated optionality trade rather than a core holding.

Key Decisions for Investors

• Long TRVI on pullbacks with a 6-12 month horizon; prefer entry after any post-rally digestion rather than chasing strength. Risk/reward is favorable only if you are underwriting 2027 data and can tolerate 20-30% drawdowns on trial headlines.
• Buy TRVI call spreads dated 9-12 months out to express upside to the next regulatory/clinical milestones while limiting downside to premium paid. Best used if implied volatility remains elevated relative to expected event timing.
• Pair trade: long TRVI / short a cash-poor, single-asset biotech with similar clinical-stage duration. The trade captures the market’s preference for balance-sheet strength while isolating financing risk as the key differentiator.
• Trim or hedge TRVI into sharp momentum spikes; the stock’s current setup is more sensitive to narrative compression than immediate fundamentals, so upside is vulnerable to any delay in the Phase 3 start or ILD expansion meeting.
• If holding common, size it as a catalyst basket position rather than a core long and set a hard stop around any FDA interaction setback. The cleanest thesis break would be a change in trial design or endpoint acceptability.